Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
GLS4/RTV and TAF Drug-drug Interaction
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04551261
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Conditions
- Interventions
- Drug: Bictegravir (BIC)Drug: Doravirine (DOR)Drug: Tenofovir alafenamide (TAF)Drug: Dolutegravir (DTG)Drug: Cabotegravir (CAB)Drug: Atazanavir/ritonavir (ATV/r)Drug: Lopinavir/ritonavir (LPV/r)Drug: Second-Line TB TreatmentDrug: CobicistatDrug: First-Line TB TreatmentDrug: Darunavir/ritonavir (DRV/r)Drug: Ritonavir
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-08-21
- Target Recruit Count
- 325
- Registration Number
- NCT04518228
- Locations
- 🇺🇸
Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
🇺🇸Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States
🇿🇦Wits RHI Shandukani Research, Johannesburg, Gauteng, South Africa
A Study of Combination Therapies to Treat COVID-19 Infection
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- ProgenaBiome
- Registration Number
- NCT04459702
- Locations
- 🇺🇸
ProgenaBiome, Ventura, California, United States
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 85
- Registration Number
- NCT04246723
- Locations
- 🇷🇺
FBIS CSRI of Epidemiology of Federal Service on Customers, Moscow, Russian Federation
🇷🇺FSIS FRC of food and biotechnology, Moscow, Russian Federation
🇷🇺SBEI HPE MSMDU n.a. A.I. Evdokimov of Ministry of Health of Russia, Moscow, Russian Federation
A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT04208061
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Inflammation and Co-Infections in D²EFT
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Kirby Institute
- Registration Number
- NCT04183738
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT04147208
- Locations
- 🇨🇳
Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Beijing YouAn Hospital,Capital Medical University, Beijing, Beijing, China
A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT04055506
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
Nucleosides And Darunavir/Dolutegravir In Africa
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 465
- Registration Number
- NCT03988452
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2019-02-07
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 420
- Registration Number
- NCT03833362
- Locations
- 🇷🇺
South-Ural State Medical University, Clinic of Medical Academy, Infectious Diseases Department, Chelyabinsk, Russian Federation
🇷🇺First Moscow State Medical University n.a. I.M. Sechenov, Clinic of Nephrology, Internal and Professional Diseases n.a. E.M. Tarleev, Moscow, Russian Federation
🇷🇺Moscow State Medical Stomatological University n.a. A. I. Evdokimov, Clinical Infectious Hospital #1, Clinical Infections Department, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.